Analysts Anticipate ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Announce -$0.27 EPS

Wall Street analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACADGet Rating) to report ($0.27) earnings per share (EPS) for the current quarter, according to Zacks. Eight analysts have issued estimates for ACADIA Pharmaceuticals’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.36). ACADIA Pharmaceuticals also reported earnings of ($0.27) per share in the same quarter last year. The business is scheduled to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that ACADIA Pharmaceuticals will report full-year earnings of ($1.32) per share for the current financial year, with EPS estimates ranging from ($1.71) to ($1.05). For the next financial year, analysts expect that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($1.35) to $0.22. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals (NASDAQ:ACADGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.27. The firm had revenue of $115.47 million for the quarter, compared to analyst estimates of $122.22 million. ACADIA Pharmaceuticals had a negative return on equity of 38.47% and a negative net margin of 43.50%. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.42) earnings per share.

Several equities analysts have recently commented on the company. Citigroup raised their price target on ACADIA Pharmaceuticals from $30.00 to $32.00 in a research note on Tuesday, March 1st. Cantor Fitzgerald raised their price target on ACADIA Pharmaceuticals from $32.00 to $37.00 and gave the company an “overweight” rating in a research note on Thursday, March 10th. StockNews.com assumed coverage on ACADIA Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Mizuho cut their target price on ACADIA Pharmaceuticals from $28.00 to $27.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 19th. Finally, The Goldman Sachs Group cut their target price on ACADIA Pharmaceuticals from $27.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, March 7th. Eleven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of “Hold” and an average target price of $29.41.

Shares of ACADIA Pharmaceuticals stock traded down $0.95 during trading on Friday, hitting $17.88. 2,028,438 shares of the stock traded hands, compared to its average volume of 1,669,818. The firm has a market cap of $2.89 billion, a P/E ratio of -13.44 and a beta of 0.67. ACADIA Pharmaceuticals has a 52-week low of $15.68 and a 52-week high of $28.06. The stock’s fifty day simple moving average is $23.38 and its 200 day simple moving average is $22.61.

In related news, CEO Stephen Davis sold 5,483 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $18.18, for a total transaction of $99,680.94. Following the completion of the sale, the chief executive officer now owns 75,875 shares of the company’s stock, valued at $1,379,407.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Srdjan R. Stankovic sold 2,865 shares of ACADIA Pharmaceuticals stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $18.18, for a total value of $52,085.70. Following the sale, the president now directly owns 55,188 shares of the company’s stock, valued at approximately $1,003,317.84. The disclosure for this sale can be found here. Insiders have sold 17,861 shares of company stock valued at $373,381 in the last ninety days. Corporate insiders own 28.50% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Lazard Asset Management LLC raised its position in ACADIA Pharmaceuticals by 19.4% during the fourth quarter. Lazard Asset Management LLC now owns 3,115 shares of the biopharmaceutical company’s stock valued at $72,000 after acquiring an additional 506 shares in the last quarter. Parallel Advisors LLC raised its position in ACADIA Pharmaceuticals by 74.8% during the fourth quarter. Parallel Advisors LLC now owns 1,365 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 584 shares in the last quarter. Voya Investment Management LLC raised its position in ACADIA Pharmaceuticals by 1.4% during the third quarter. Voya Investment Management LLC now owns 47,779 shares of the biopharmaceutical company’s stock valued at $794,000 after acquiring an additional 644 shares in the last quarter. Allworth Financial LP raised its position in ACADIA Pharmaceuticals by 1,081.3% during the fourth quarter. Allworth Financial LP now owns 1,075 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 984 shares in the last quarter. Finally, Personal CFO Solutions LLC raised its position in ACADIA Pharmaceuticals by 6.7% during the first quarter. Personal CFO Solutions LLC now owns 15,846 shares of the biopharmaceutical company’s stock valued at $384,000 after acquiring an additional 1,000 shares in the last quarter. Institutional investors own 91.74% of the company’s stock.

About ACADIA Pharmaceuticals (Get Rating)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Read More

Get a free copy of the Zacks research report on ACADIA Pharmaceuticals (ACAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.